Advanced Kidney Cancer Clinical Trial
Official title:
A Prospective Single-arm Clinical Study of Pembrolizumab Combined With Lenvatinib Neoadjuvant Therapy in Patients With Advanced Renal Cance
This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer. Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles pre-operation and patients need to continue taking the drug for a year after surgery.
This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation.Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles pre-operation and patients need to continue taking the drug for a year after surgery. The main objective of the study was to evaluate whether the treatment was beneficial to patients undergoing surgery. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05485883 -
Tislelizumab Plus Lenvatinib in Stage III-IV RCC
|
Phase 2 | |
| Active, not recruiting |
NCT03308396 -
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03540199 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer
|
Phase 2 |